# Selcodebart PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/selcodebart

> The next catalyst for selcodebart, sponsored by Disc Medicine, Inc. (IRON), is its interim data readout, 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, half-year only, exact day, quarter only, year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What is the next FDA catalyst for selcodebart?

The next catalyst for selcodebart, sponsored by Disc Medicine, Inc. (IRON), is its interim data readout, 2027. Press release filed with the SEC (EX-99): "Progressing Phase 2 study of selcodebart in patients with inflammatory bowel disease (IBD) with initial data expected in 2027" [Calendar and source filings](https://sec-api.dev/pdufa/selcodebart)

Source: Press release filed with the SEC (EX-99), accession 0001193125-26-448711, https://www.sec.gov/Archives/edgar/data/1816736/000119312526448711/iron-ex99_1.htm (retrieved 2026-11-12). Last confirmed 2026-11-05. Cite: https://sec-api.dev/pdufa/selcodebart#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | selcodebart |
| Codes | DISC-0974 |
| Sponsor | Disc Medicine, Inc. (IRON) https://sec-api.dev/companies/iron/catalysts |
| Indications | [ibd and anemia](https://sec-api.dev/indications/ibd-and-anemia), anemia of mf, inflammatory bowel disease, anemia of mf with initial data, anemia of myelofibrosis, anemia of different inflammatory diseases |
| Modality |  |
| FDA designations | orphan |

## Timeline

### Jun 2022: trial start

- Status: completed. Date confidence: month. Stage: 1/2. Indication: anemia of different inflammatory diseases.
- First seen 2025-02-27, last confirmed 2025-02-27.
- SEC Form 10-K (accession 0000950170-25-028390): "Based on these findings, we initiated two Phase 1b/2 clinical trials of DISC-0974 in patients with anemia of different inflammatory diseases: a Phase 1b/2 clinical trial of DISC-0974 in patients with anemia of MF, which was initiated in June 2022, and a separate Phase 1b/2 clinical trial of DISC-0974 in patients with non-dialysis dependent CKD and anemia, which was initiated in February 2023." https://www.sec.gov/Archives/edgar/data/1816736/000095017025028390/iron-20241231.htm
- SEC Form 10-K (accession 0000950170-25-028390): "In June 2022, we initiated an open-label, multi-center, Phase 1b/2 trial to evaluate the safety, tolerability, and efficacy of DISC-0974 in patients with anemia of MF." https://www.sec.gov/Archives/edgar/data/1816736/000095017025028390/iron-20241231.htm

### Feb 2023: trial start

- Status: completed. Date confidence: month. Stage: 1.
- First seen 2025-02-27, last confirmed 2026-02-26.
- SEC Form 10-K (accession 0001193125-26-073602): "In February 2023, we initiated a Phase 1b clinical trial to evaluate the safety, tolerability and efficacy of DISC-0974 in patients with CKD who are not receiving dialysis and are anemic." https://www.sec.gov/Archives/edgar/data/1816736/000119312526073602/iron-20251231.htm
- SEC Form 10-K (accession 0000950170-25-028390): "In February 2023, we initiated a Phase 1b/2 clinical trial to evaluate the safety, tolerability and efficacy of DISC-0974 in patients with CKD who are not receiving dialysis and are anemic." https://www.sec.gov/Archives/edgar/data/1816736/000095017025028390/iron-20241231.htm

### late 2024: trial start

- Status: scheduled. Date confidence: half. Stage: 2.
- First seen 2024-11-12, last confirmed 2024-11-12.
- Press release filed with the SEC (EX-99) (accession 0001193125-24-255200): "The Company expects to initiate a Phase 2 study in anemia of myelofibrosis (MF) by the end of 2024" https://www.sec.gov/Archives/edgar/data/1816736/000119312524255200/d911918dex991.htm

### Dec 2024: trial start

- Status: completed. Date confidence: month. Stage: 2. Indication: anemia of MF.
- First seen 2025-02-27, last confirmed 2026-02-26.
- SEC Form 10-K (accession 0001193125-26-073602): "In December 2024, we initiated RALLY-MF, the open-label Phase 2 portion of this clinical trial to evaluate the safety, tolerability and efficacy of DISC-0974 in patients with anemia of MF." https://www.sec.gov/Archives/edgar/data/1816736/000119312526073602/iron-20251231.htm
- SEC Form 10-Q (accession 0001816736-25-000007): "In January 2025, the Company dosed the first patient in the Phase 2 clinical trial of DISC-0974." https://www.sec.gov/Archives/edgar/data/1816736/000181673625000007/iron-20250630.htm
- SEC Form 10-K (accession 0000950170-25-028390): "In December 2024, we initiated the open-label Phase 2 part of our Phase 1b/2 clinical trial to evaluate the safety, tolerability and efficacy of DISC-0974 in patients with anemia of MF." https://www.sec.gov/Archives/edgar/data/1816736/000095017025028390/iron-20241231.htm
- SEC Form 10-K (accession 0000950170-25-028390): "In January 2025, we dosed the first patient in the Phase 2 clinical trial of DISC-0974." https://www.sec.gov/Archives/edgar/data/1816736/000095017025028390/iron-20241231.htm
- SEC Form 10-K (accession 0000950170-25-028390): "In January 2025, the Company dosed the first patient in the Phase 2 clinical trial of DISC-0974." https://www.sec.gov/Archives/edgar/data/1816736/000095017025028390/iron-20241231.htm
- SEC Form 10-K (accession 0000950170-25-028390): "In December 2024, we presented additional analyses of the Phase 1b study in anemia of MF and initiated the open-label Phase 2 portion of this clinical trial in patients with anemia of MF." https://www.sec.gov/Archives/edgar/data/1816736/000095017025028390/iron-20241231.htm
- SEC Form 10-K (accession 0000950170-25-028390): "In December 2024, we presented additional analyses of the Phase 1b study in anemia of MF and initiated a Phase 2 open-label clinical trial in patients with anemia of MF." https://www.sec.gov/Archives/edgar/data/1816736/000095017025028390/iron-20241231.htm

### March 31, 2025: trial start

- Status: completed. Date confidence: exact. Stage: 2.
- First seen 2025-05-07, last confirmed 2025-05-07.
- SEC Form 10-Q (accession 0000950170-25-065069): "During the three months ended March 31, 2025, the Company dosed the first patient in the Phase 2 clinical trial of DISC-0974." https://www.sec.gov/Archives/edgar/data/1816736/000095017025065069/iron-20250331.htm

### Q4 2025: interim data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: anemia of MF with initial data.
- First seen 2025-01-10, last confirmed 2025-10-20.
- Press release filed with the SEC (EX-99) (accession 0001816736-25-000006): "Progressing RALLY-MF Phase 2 study of DISC-0974 in patients with anemia of MF with initial data expected in Q4 2025 o" https://www.sec.gov/Archives/edgar/data/1816736/000181673625000006/iron-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-065031): "Progressing ongoing Phase 2 study of DISC-0974 in patients with anemia of MF with initial data expected in H2 2025" https://www.sec.gov/Archives/edgar/data/1816736/000095017025065031/iron-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-003859): "Initial data from an ongoing phase 2 study of DISC-0974 (anti-hemojuvelin antibody) in anemia of myelofibrosis (MF) expected H2 2025" https://www.sec.gov/Archives/edgar/data/1816736/000095017025003859/iron-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-037650): "ASH 2024; initial data from ongoing Phase 2 expected in H2 2025" https://www.sec.gov/Archives/edgar/data/1816736/000119312525037650/d916827dex991.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-003859): "Progress ongoing phase 2 MF anemia trial with initial data expected H2 2025" https://www.sec.gov/Archives/edgar/data/1816736/000095017025003859/iron-ex99_1.htm
- SEC Form 8-K (accession 0001193125-25-242959): "Initial data from ongoing Phase 2 study in anemia of MF to be reported by year end; topline data expected in 2026, if positive, is anticipated to support discussion with regulatory agencies on registrational path" https://www.sec.gov/Archives/edgar/data/1816736/000119312525242959/d272031d8k.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-242959): "Initial data from ongoing Phase 2 study in anemia of MF to be reported by year end; topline data expected in" https://www.sec.gov/Archives/edgar/data/1816736/000119312525242959/d272031dex991.htm

### 2026: interim data readout

- Status: scheduled. Date confidence: year. Stage: 2. Indication: anemia of myelofibrosis.
- First seen 2025-11-06, last confirmed 2025-11-06.
- Press release filed with the SEC (EX-99) (accession 0001193125-25-268196): "Initial data from Phase 2 RALLY-MF trial of DISC-0974 in patients with anemia of myelofibrosis (MF) to be presented at ASH Annual Meeting in December, with topline data expected in 2026" https://www.sec.gov/Archives/edgar/data/1816736/000119312525268196/iron-ex99_1.htm

### Q1 2026: trial start

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: IBD and anemia.
- First seen 2025-10-20, last confirmed 2025-11-06.
- Press release filed with the SEC (EX-99) (accession 0001193125-25-242959): "We also continue to drive our expansion strategy for both of these programs with a plan to initiate a Phase 2 trial of DISC-0974 in anemia of inflammatory bowel disease in 2026 and a Phase 1b trial of" https://www.sec.gov/Archives/edgar/data/1816736/000119312525242959/d272031dex991.htm
- SEC Form 10-Q (accession 0001193125-25-268200): "For example, we plan to initiate a Phase 2 clinical trial of DISC-0974 in patients with IBD and anemia in the first quarter of 2026, and we are planning exploratory studies in additional patient populations with anemia of chronic disease." https://www.sec.gov/Archives/edgar/data/1816736/000119312525268200/iron-20250930.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-242959): "Initiation of Phase 2 study in IBD anemia Suppression anticipated in Q1 2026" https://www.sec.gov/Archives/edgar/data/1816736/000119312525242959/d272031dex992.htm

### Q4 2026: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2.
- First seen 2025-11-06, last confirmed 2026-05-05.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-205187): "Topline data from the RALLY-MF study to be shared in Q4 2026, with an end of Phase 2 meeting with the FDA expected to occur by end of year" https://www.sec.gov/Archives/edgar/data/1816736/000119312526205187/iron-ex99_1.htm
- SEC Form 10-K (accession 0001193125-26-073602): "We expect to report topline data from our RALLY-MF Phase 2 trial in 2026, which, if positive, are expected to support discussions with regulatory agencies on the potential regulatory path for DISC-0974 in anemia of MF." https://www.sec.gov/Archives/edgar/data/1816736/000119312526073602/iron-20251231.htm
- SEC Form 10-K (accession 0001193125-26-073602): "Topline data from this trial is expected in the second half of 2026, which, if positive, is expected to support discussions with regulatory agencies on the potential regulatory path for DISC-0974 in anemia of MF." https://www.sec.gov/Archives/edgar/data/1816736/000119312526073602/iron-20251231.htm
- SEC Form 10-Q (accession 0001193125-25-268200): "Topline data from this trial is expected in 2026, which, if positive, is expected to support discussions with regulatory agencies on the potential regulatory path for DISC-0974 in anemia of MF." https://www.sec.gov/Archives/edgar/data/1816736/000119312525268200/iron-20250930.htm

### 2027: interim data readout

- Status: scheduled. Date confidence: year. Stage: 2. Indication: IBD and anemia.
- First seen 2026-05-05, last confirmed 2026-11-05.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-448711): "Progressing Phase 2 study of selcodebart in patients with inflammatory bowel disease (IBD) with initial data expected in 2027" https://www.sec.gov/Archives/edgar/data/1816736/000119312526448711/iron-ex99_1.htm
- SEC Form 10-Q (accession 0001193125-26-448729): "We also initiated RALLY-IBD, a Phase 2 clinical trial of selcodebart in patients with IBD and anemia in the first quarter of 2026, with initial data anticipated in 2027, and we are planning exploratory studies in additional patient populations with anemia of chronic disease." https://www.sec.gov/Archives/edgar/data/1816736/000119312526448729/iron-20260930.htm
- SEC prospectus (424B) (accession 0001193125-26-450184): "We also initiated RALLY-IBD, a Phase 2 clinical trial of selcodebart in patients with IBD and anemia in the first quarter of 2026, with initial data anticipated in 2027, and we are planning exploratory studies in additional patient populations with anemia of chronic disease." https://www.sec.gov/Archives/edgar/data/1816736/000119312526450184/d187305d424b5.htm
- SEC prospectus (424B) (accession 0001193125-26-427982): "We also initiated RALLY-IBD, a Phase 2 clinical trial of selcodebart in patients with IBD and anemia in the first quarter of 2026, with initial data anticipated in 2027, and we are planning exploratory studies in additional patient populations with anemia of chronic disease." https://www.sec.gov/Archives/edgar/data/1816736/000119312526427982/d190758d424b5.htm
- SEC prospectus (424B) (accession 0001193125-26-425425): "We also initiated RALLY-IBD, a Phase 2 clinical trial of selcodebart in patients with IBD and anemia in the first quarter of 2026, with initial data anticipated in 2027, and we are planning exploratory studies in additional patient populations with anemia of chronic disease." https://www.sec.gov/Archives/edgar/data/1816736/000119312526425425/d190758d424b5.htm
- SEC Form 10-Q (accession 0001193125-26-325034): "We also initiated RALLY-IBD, a Phase 2 clinical trial of selcodebart in patients with IBD and anemia in the first quarter of 2026, with initial data anticipated in 2027, and we are planning exploratory studies in additional patient populations with anemia of chronic disease." https://www.sec.gov/Archives/edgar/data/1816736/000119312526325034/iron-20260630.htm
- SEC Form 10-Q (accession 0001193125-26-205192): "We also initiated a Phase 2 clinical trial of DISC-0974 in patients with IBD and anemia in the first quarter of 2026, with initial data anticipated in 2027, and we are planning exploratory studies in additional patient populations with anemia of chronic disease." https://www.sec.gov/Archives/edgar/data/1816736/000119312526205192/iron-20260331.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-325031): "Progressing Phase 2 study in patients with inflammatory bowel disease (IBD) with initial data expected in 2027" https://www.sec.gov/Archives/edgar/data/1816736/000119312526325031/iron-ex99_1.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/selcodebart.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Selcodebart PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/selcodebart

```bibtex
@misc{secapidev_pdufa_selcodebart_20261116,
  title        = {Selcodebart PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/selcodebart}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_selcodebart_20261116","title":"Selcodebart PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/selcodebart","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
